Abstract. Endometrial carcinoma (EC) is the most common malignancy in women. Dispite its prevalence, the prognosis of endometrial carcinoma still relies on conventional histological type, grade and invasion information. Its morbidity is still increasing and the outcome is very poor. To the best of our knowledge, hormonal imbalance and/or molecular genetic alterations are the main cause of EC. However, the alterations of lncRNAs which accounts for approximately 4/5 of human transcripts are still poorly understood. In the present study, using the RiboArray™ Custom Array, we studied the expression profiles of lncRNA in EC as compared to normal endometrium (NE) to find potential core lncRNAs for the diagnosis of EC. We found the potential core lncRNA by GO, KEGG, lncRNA and mRNA co-expression network. The potential functional lncRNAs were further detected by qPCR to validate the microarray results. A total of 172 lncRNAs and 188 mRNAs were found to be differentially expressed between type Ⅰ EC and the NE samples (fold change >1.5). qPCR validation showed good consistency with the microarray data. GO, pathway analysis, the lncRNA and mRNA co-expression network as well as the TCGA data revealed that 6 lncRNAs (KIAA0087, RP11-501O2, FAM212B-AS1, LOC102723552, RP11-140I24 and RP11-600K151) may be the core regulators of endometrial carcinogenesis. The potential core lncRNAs revealed by the mRNA and lncRNA co-expression network might be helpful to explore potential early diagnostic and therapeutic targets for EC.
Introduction
Endometrial carcinoma is the most frequent malignancy in female genital tract accounting for 1-2% mortality rate of all cancer in the western world (1) . According to the statistic data collected from 2000 to 2011 in China, the morbidity has increased by 3.7% every year (2) . Lack of an early diagnostic marker and therapeutic targets is the main cause of EC deaths.
In general, EC is mainly classified into two major types (type Ⅰ and type Ⅱ). Type Ⅰ ECs comprise 80% of new cases (3) . They are histologically well and moderately differentiated, estrogen-dependent and less prone to be aggressive. Type Ⅱ ECs are mostly low differentiated, estrogen-independent and with a tendency to recur, even at early stage. The hormonal imbalance and the genetic alterations are proved to be the main cause of EC (4, 5) . Most of EC cases are diagnosed after menopause. The use of estrogen only replacement therapy and late menopause onset can increase the risk of EC. Genetic alteration, such as MLH1 (6) , MSH2 (7), PMS2 (8) , MSH6 (9), ARID1A (10), PTEN (11) , KRAS2 (12), CTNNB1 (13), RB1 (11) , TP53 (12) , c-Kit (14) gene mutations or gene loss have been demonstrated to be associated with the increased risk of EC, ATR mutation in endometrioid carcinoma (EEC) is associated with aggressiveness of the EEC (15) . Thus, we believe that new molecular-based subtype classification can help for the early diagnosis and treatment decision.
Recently, the non-coding RNAs, including miRNA, lncRNAs (longer than 200 bp, not encoding proteins, transcribed by RNA polymerase Ⅱ) which account for approximately 4/5 of all human transcripts are proved to be critical regulators of cancers, including EC. They are involved in nearly all of the metastatic processes of cancer, such as proliferation, invasion and metastasis through regulating the protein coding gene expression transcriptionally, post-transcriptionally or by functioning as a scaffold of the lncRNA, miRNA and protein interaction (16) . Besides, a variety of lncRNAs have been found to be the prognostic marker of diseases, such as breast (17) , lung (18) and ovarian cancer (19) . Thus, the exploration of lncRNA expression profile is essential for the discovery of early diagnostic markers and the potential therapeutic candidates. Notably, Zhai et al (20) , reported the differentially lncRNA in randomly selected in EC samples and the adjacent non-tumor tissues. However, the mechanism of the type Ⅰ EC and type Ⅱ EC is quite different, the differential lncRNAs in type Ⅰ EC and the normal endometrium (NE) from the uterine leiomyoma patients which will give us the important information of the potential early diagnostic marker is poorly understood. In the present study, we aimed to find the potential early diagnostic and therapeutic candidates of lncRNAs for EC. We first utilized the high throughput lncRNA microarray analysis to find the differentially expressed lncRNAs. Then, we further analyzed the lncRNA function by Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), mRNA-lncRNA co-expression network as well as the TCGA database to find the potential core lncRNAs that may be involved in EC. This would be helpful for exploring the mechanism of EC development as well as for prediction of clinical outcomes. lncRNA microarray profiling. To find the potential roles of lncRNA function in EC, we first examined the differentially expressed lncRNA by microarray profiling (Fig. 1 ). lncRNAs were collected from the authoritative database NCBI-GRCh38, ENA, vEGA, RNAcentral, HANAvA, ENSEMBL, RFAM (Fig. 1A) . In the data, a total of 17899 lncRNA and 26363 mRNA were detected with 172 lncRNA and 188 mRNA differentially expressed between type Ⅰ EC (stage Ⅰ/Ⅱ) and their relative control endometrium (fold >1.5 and P<0.05) as Table I . Details of primer pairs used in analysis of lncRNA and mRNA expression by qRT-PCR.
Distinct expression profile of lncRNA in endometrial carcinoma

Materials and methods
Preparation
Gene
Forward primer (5'-3') Reverse primer (5'-3')   KIAA0087  TCGGGGGACCGAGAAATACT  CCAGTCCAAGAGAAGCAGCA  RP11-508N22  TTAGCAGCACATGCTCACCA  GGTAAGTAGCTGGGCTGTGG  RP11-501O2  ACGATGAGACTTGGTGCTGAA  TGGTCCTGTTTCTCGCTGAC  FAM212B-AS1  CCAGAGAAGAAAGGCAGCGA  ACTCCTTCGCGTGTTCAGTT  LOC102723552  ACGAGATGCAGAAGATTACGC  TGAAATCTTACCTGACTGCAGATT  RP11-140I24  TCAGTCGTCTTCACGCTTCC  CAGATTAGCTGGCAGAGGGG  RP11-600K151  AGGGCTCAGTAGATTTGCCC  AGGCAGCATCTCACCTAACG  ALCAM  CTGGAGTACAAGACAACCAAGG  GTCACCTGCTCTGTAGGATAG  POLR3E  TTTCAGTACCCTGTGCGTCC  TGGGCTTGATCTTGGCTGAG  TDRD10 GGAGATCCTGTTGGAAAGCA GCCAACATACACCTCTGTCTC
shown in the scatter plot data ( Fig. 1B and D) (the red dots indicate the differentially expressed lncRNA and mRNA with fold >1.5 and P<0.05) and clustering data ( Fig. 1C and E ; fold >1.5 and P<0.05). The detailed information of the differentially lncRNAs and mRNAs are presented in Tables II and III with the fold change >5 and P<0.05.
Expression signature of dysregulated lncRNAs in EC compared to NE.
To investigate the signature of the dysregulated lncRNAs in EC, we studied the dysregulated lncRNA classification, lengths and chromosome distribution (Fig. 2) .
In the present study, the majority of the lncRNAs that were differentially expressed in EC were intergenic lncRNAs, antisense lncRNAs as well as the TEC (to be experimentally confirmed) lncRNAs ( Fig. 2A) . The lncRNA lengths are mainly between 400 and 64000 bp (Fig. 2B) . The upregulated lncRNAs and the downregulated lncRNAs are distributed in different chromosomes ( Fig. 2C and D) .
GO and pathway analysis. To explore the potential function of the dysregulated lncRNAs in EC, we predicted the lncRNA target genes according to their chromosome location. In addition, we carried out GO and pathway analysis of these lncRNAs. The Gene Ontology consortium which incorporate many databases and developed three ontologies (biological processes, cellular components and molecular functions) (http://www.geneontology.org) revealed that numerous biological processes, cellular components and molecular function are altered in EC compared to control (Fig. 3A-C) . To find which pathways are altered, we also mapped the genes to KEGG pathways. It is noteworthy that the plasma components which are the main components during cell response to the intracellular or extracellular signals, such as the cell adhesion molecules are the most dysregulated molecules in EC as shown in the result of biological pathway analysis, the cellular component and KEGG pathway analyses (Fig. 3A,  C and D) . Besides, the structure specific DNA binding components which may function during transcription and the oxidoreductase component which may be involved in cell metabolism and other processes are also dysregulated in EC (Fig. 3B) . Cell adhesion molecules are important for tissue integrity and also cell migration in tumor cells or other developmental cells (16, 21) . E-cadherin, N-cadherin and integrins which are the most famous adhesion molecules have been demonstrated to be associated with cell invasion of various cancer types (22) (23) (24) , the transmembrane glycoprotein ALCAM (also known as CD166) which belongs to the immunoglobulin superfamily has been considered as the marker of breast cancer (25) . In the present study, the cell adhesion molecules, such as ALCAM are also the most dysregulated mRNA.
mRNA-lncRNA co-expression network. lncRNA function has been implicated in several steps of carcinogenesis by acting as structural, catalytic or regulatory RNA or interacting with DNA, RNA and protein (16) . However, only a few lncRNA functions have been elucidated. mRNA and lncRNA co-expression network, which can provide evidence for the involvement of new genes or lncRNAs in core biological functions, is very important for the prediction of the lncRNA function preliminarily (19, 26) . Thus, we carried out the lncRNA and mRNA co-expression network in Guangzhou RiboBio Co. The co-expression network in Fig. 4A shows that ALCAM is co-expressed with 5 lncRNAs (ENST00000624279:RP11-140I24, LOC102723552, KIAA0087, RP11-600K151 and FAM212B-AS1) and 1 mRNA (POLR3E), POLR3E is co-expressed with 6 lncRNAs (FAM212B-AS1, RP11-140I24, LOC102723552, RP11-508N22, RP11-501O2 and KIAA0087) and 2 mRNAs (ALCAM and TDRD10), TDRD10 is co-expressed with 3 lncRNAs (RP11-600K151, RP11-508N22 and KIAA0087) and 1 mRNA (POLR3E) which are differentially expressed in EC (>5-fold, P<0.05). Real-time PCR verified that 6 of the 7 lncRNAs and all of the 3 mRNAs are dramatically downregulated in EC, which is consistent with the microarray data ( Fig. 4B and C) . Interestingly, most of these lncRNAs are relatively conserved between human, rhesus, rat and mouse as analyzed using uCSC website (http:// genome.ucsc.edu/) (data not shown).
The Cancer Genome Atlas (TCGA) database includes most of the tumor types and information on each case for community research use. cBioPortal for Cancer Genomics provides visualization and analysis of the TCGA datasets. Notably, the results presented in the cBioPortal of cancer genomics (http:// www.cbioportal.org/) showed that EC cases with ALCAM, TDRD10 and/or POLR3E alterations showed poorer overall survival rate as compared with cases without alterations of these genes (Fig. 4D) .
Discussion
According to the ENCODE Project Consortium, the protein coding genes only account for 1% of the human genome (27) . Most of the regions are not transcribed, such as a large class of the non-coding RNA. lncRNA functions as structural, catalytic, regulatory RNAs have been found to be involved in a variety of processes, such as development (18) , tumorigenesis (16), cardiovascular disease (28) and neurodegenerative diseases (29) . Similarly to the protein coding genes, lncRNAs which are distributed in the cytoplasm, nucleus and also transported to the extracellular matrix can be identified as the biomarkers of various diseases. For example, studies found that lncRNA-DANCR can be used as a prognostic biomarker of hepatocellular carcinoma (30) . The circulating lncRNA-LIPCAR can be used to predict survival of patients with heart failure (31) . lncRNAs are also known as biomarkers or therapeutic target of cancers, such as breast (32) , lung (33) and ovarian cancer (19) . Since most of the lncRNAs function through the regulation of the mRNAs the lncRNA-mRNA co-expression network provides us with a powerful platform for the prediction of the lncRNA function (19) . For example, RP11-284N8.3.1 and AC104699.1.1 which were identified using the lncRNA-mRNA co-expression network are found to be the independent predictive biomarkers of ovarian cancer (19) . In this study, we first used microarray analysis to find the differentially expressed lncRNAs in EC, and then by using GO and KEGG as well as the lncRNA-mRNA co-expression network, we predicted that the 6 lncRNAs and 3 mRNAs are probably the early biomarkers of EC.
The glycolysis which produces ATP more quickly is strongly enhanced in tumor cells (34, 35) . Here, we used the GO analysis to prove that the main molecular function involved is the oxidoreductase activity, emphasizing the difference between the metabolism between the tumor and normal tissue (Fig. 3B) .
The adhesion molecules have been demonstrated to be the important regulators of endometrial epithelium integrity, its decreased expression will disrupt the integrity of the NE and may be involved in the pathology of the endometrium (22) . Asthma which affects 5-10% of the population may increase the patients' risk of cancer is also altered in EC as compared with control (36) . The chronic inflammatory disease associated gene has been found to help cancers metastasize and may be the predictor of brain cancer in children (37, 38) . Notably, the KEGG analysis showed that the adhesion molecules and asthma associated genes are the top two differentially altered pathways in EC.
Endometrial carcinoma which is a common malignancy of female reproductive tract accounts for ~1-2% of the tumor deaths in the western world (1) . It is also becoming more prevalent in China each year. Thus, it is very urgent for us to find the predictive biomarkers of EC. Here, in order to find whether lncRNAs can be used as EC biomarkers, we performed the lncRNA microarray. By using the microarray data and the lncRNA-mRNA co-expression network, we found 6 lncRNAs (KIAA0087, RP11-501O2, FAM212B-AS1, LOC102723552, RP11-140I24 and RP11-600K151) and 3 mRNAs (ALCAM, TDRD10 and POLR3E) that are functionally related in EC. Interestingly, ALCAM is highly expressed in the endometrium glandular cells and its expression was decreased in ~50% of the endometrial cancer tissues while POLR3E is moderately expressed in the endometrium glandular cells and its expression was decreased in ~50% of EC according to the human protein atlas website which is consistent with our data (http:// www.proteinatlas.org/). The TCGA data also confirmed that these three gene alterations indicated poorer overall survival as compared with the cases without these gene alterations. We also validated that the lncRNAs which are co-expressed with these three mRNAs are downregulated in EC.
Since the mechanism of the type Ⅰ EC and type Ⅱ EC is quite different, distinguish the different type of EC is quite important. Different from the differentially expressed lncRNAs between the randomly selected EC samples and the adjacent non-tumor tissue reported before (20) , we reported the differentially expressed lncRNAs in type Ⅰ EC as compared with NE using the microarray and the lncRNAs and mRNA co-expression network for the first time. The differentially expressed lncRNAs may be indicators of the type Ⅰ EC and may provide the potential information for the evaluation of EC.
